Pharmacogenomic overlap between antidepressant treatment response in major depression & antidepressant associated treatment emergent mania in bipolar disorder.

"Competing interests NAN reports no financial relationships with commercial interests. BJC reports no financial relationships with commercial interests. LMB reports no financial relationships with commercial interests. AO reports no financial relationships with commercial interests. MGR reports no financial relationships with commercial interests. FRN receives grant support from the National Institute of Mental Health K23 Award (K23MH120503) and from a 2017 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation; has a U.S. Patent and Trademark Office patent # 10,857,356; receives consultant fees from Otsuka Pharmaceutical and has received non-financial research support from Soterix Medical. DJB has received research support from NIDA, NuBiyota, the University of Minnesota Foundation, and the University of Minnesota Department of Psychiatry and Behavioral Sciences MV reports no financial relationships with commercial interests. BS received grant support from Mayo Clinic. KMM reports no financial relationships with commercial interests. HKB reports no financial relationships with commercial interests. SK reports no financial relationships with commercial interests. MFS reports no financial relationships with commercial interests. ME reports no financial relationships with commercial interests. AM reports no financial relationships with commercial interests. JASR reports no financial relationships with commercial interests. GJ reports no financial relationships with commercial interests. AB reports no financial relationships with commercial interests. JGL reports no financial relationships with commercial interests. ACB reports no financial relationships with commercial interests. SJT reports no financial relationships with commercial interests. SLM is or has been a consultant to or member of the scientific advisory boards of Avanir, Allergan (now AbbVie), Bracket (now Signant Health), Idorsia, Intra-Cellular Therapies, Inc., Naurex, Otsuka, Shire (now Takeda), Sunovion, and Takeda. She is or has been a principal or co-investigator on studies sponsored by the Agency for Healthcare Research & Quality (AHRQ), Avenir, AstraZeneca, Cephalon, Forest, Jazz, Marriott Foundation, Medibio, National Institute of Mental Health, Orexigen Therapeutics, Inc., Otsuka, Shire (now Takeda), Sunovian, and Takeda Pharmaceutical Company Ltd. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent. JMB reports no financial relationships with commercial interests. MAF has received grant support from Assurex Health and Mayo Foundation, received CME travel and honraria from Carnot Laboratories, and has Financial Interest/Stock ownership/Royalties from Chymia LLC."

"We acknowledge Regeneron Genetics Center for providing genetic data for a portion of the bipolar biobank participants for the analysis. Project Generation were supported in part by Mayo Clinic’s Center for Individualized Medicine. Funding for the study was provided by the Marriott Foundation and the Dauton Family. The foundation and family had no further role in the study design, analysis or interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication. We would also like to thank Mr. Larry Prokop from the Mayo Clinic Library, Mayo Clinic Rochester, MN, USA for helping and conducted the literature search. Presented at the Annual meeting of the Society of Biological Psychiatry. San Diego, April 27–29, 2023."